# Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

> **NCT06895473** · PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 26 (estimated)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cytarabine
- **PROCEDURE:** Lumbar Puncture
- **DRUG:** Methotrexate
- **DRUG:** Therapeutic Hydrocortisone

## Key facts

- **NCT ID:** NCT06895473
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895473, "Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06895473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*